ARTICLE | Clinical News
Herceptin trastuzumab regulatory update
December 17, 2001 8:00 AM UTC
The FDA approved an sBLA from DNA to include median survival data in the label for DNA's Herceptin anti-HER-2 antibody to treat metastatic breast cancer. The FDA also is reviewing a DNA sBLA to allow ...